ERBB3 and non-small cell lung carcinoma: Emerging clinical evidence supports this hypothesis. In a small trial of T-DXd in non-small cell lung cancer patients, the activity of T-DXd was shown to be independent of HER2 over-expression in HER3 + , 2 + , or 1 + tumors [47].